Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma

Fig. 1

Schematic of study design. Subjects who met eligibility criteria during screening were randomized to receive three consecutive daily doses of either DAS 181 or placebo starting on day 0, the first day of the initial period. Subjects were evaluated at specified time-points for an additional 18 days, then crossed-over to the other treatment group within 6 weeks of completing the initial period. Abbreviations: I = initial; CO = crossover

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us